ArticleFrontiers in genetics2022

HRD-MILN: Accurately estimate tumor homologous recombination deficiency status from targeted panel sequencing data.

Xuwen Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.